ISSN: 2456 - 530X
PubMed - National Library of Medicine - ID: 101737738

EIJO: Journal of Ayurveda, Herbal Medicine and Innovative Research (EIJO - AHMIR)
Einstein International Journal Organization (EIJO)
Available Online at: www.eijo.in
Volume – 11, Issue – 1, January – February - 2026, Page No. : 12 - 22

Advances in Pharmacological Research: Integrative Roles of Natural Products, Synthetic Therapeutics, and Combination Drug Strategies

[1]Narsingh Rajpoot, [2]Shivakshi Shukla, [3]Rohitash Sharma, [4]Vipin Kumar Singhal

[1-4]Jaipur School of Pharmacy, Maharaj Vinayak Global University, Jaipur, Rajasthan

Corresponding Author: Narsingh Rajpoot, Jaipur School of Pharmacy, Maharaj Vinayak Global University, Jaipur, Rajasthan.

Type of Publication: Original Research Article

Conflicts of Interest: Nil

Abstract

Pharmacological research has evolved considerably with the integration of natural products, synthetic therapeutics, and combination drug strategies to improve therapeutic efficacy, safety, and patient outcomes. Natural products remain an essential source of bioactive compounds with diverse pharmacological activities, while synthetic drugs offer precise molecular targeting, improved pharmacokinetics, and scalability in production. Recently, combination drug strategies have gained significant attention due to their ability to enhance therapeutic effectiveness, reduce drug resistance, and minimize adverse effects. Advances in biotechnology, computational drug design, and systems pharmacology have facilitated the development of innovative therapeutic approaches that integrate these three domains. This review highlights current progress in pharmacological research, focusing on natural product-derived compounds, synthetic drug innovations, and rational combination therapies. The challenges, opportunities, and future perspectives in integrative pharmacology are also discussed to provide insights into next-generation therapeutic development.

Keywords: Pharmacological Research, Natural Products, Synthetic Therapeutics, Combination Therapy, Drug Discovery, Integrative Pharmacology, Personalized Medicine, Drug Resistance.

1. Introduction

Pharmacological research represents a cornerstone of modern healthcare, contributing significantly to drug discovery, therapeutic innovation, disease prevention, and clinical management. The discipline encompasses the study of drug sources, mechanisms of action, pharmacokinetics, pharmacodynamics, safety, efficacy, and therapeutic applications. Over the past few decades, rapid advances in scientific technologies, interdisciplinary collaboration, and global health challenges have accelerated the evolution of pharmacological research. These developments have enabled the discovery of novel therapeutic agents, improved treatment strategies, and enhanced understanding of disease mechanisms, ultimately leading to better patient outcomes.

Historically, natural products have played a fundamental role in the development of medicines. Medicinal plants, microbial metabolites, and marine-derived compounds have served as rich reservoirs of bioactive molecules for centuries. Traditional medical systems relied heavily on botanical remedies for treating various ailments, and many modern pharmaceuticals trace their origins to natural sources. Natural compounds often possess structural diversity and biological

activities that are difficult to replicate synthetically, making them valuable templates for drug discovery. Their therapeutic potential includes antimicrobial, anti-inflammatory, anticancer, antioxidant, and metabolic regulatory effects, which continue to inspire ongoing pharmacological investigations.

Despite their importance, natural product-based drug discovery faces several challenges. Variability in phytochemical composition due to environmental, geographical, and seasonal factors can affect therapeutic consistency. Standardization, quality control, bioavailability, and large-scale production remain critical issues requiring innovative solutions. Advances in analytical chemistry, biotechnology, and formulation science are helping address these challenges by improving compound isolation, characterization, and delivery systems. Modern extraction techniques and high-throughput screening methods have further enhanced the efficiency of natural product research, enabling identification of promising lead compounds for drug development.

With the progression of organic chemistry, medicinal chemistry, and molecular biology, synthetic therapeutics emerged as a powerful complement to natural product-based drug discovery. Synthetic drugs offer several advantages, including precise structural modification, enhanced pharmacokinetic properties, improved stability, and scalable manufacturing processes. Rational drug design, supported by computational modeling, molecular docking, and structure–activity relationship studies, allows scientists to develop molecules with high specificity toward biological targets such as enzymes, receptors, or signaling pathways. This targeted approach has led to significant therapeutic advances in managing chronic and complex diseases.

Biotechnological innovations have further expanded the scope of synthetic therapeutics. Recombinant DNA technology, monoclonal antibody development, gene therapy, and biologics have revolutionized treatment modalities across various disease conditions. These therapies provide targeted mechanisms of action and improved therapeutic precision compared with traditional small-molecule drugs. However, synthetic therapeutics are not without limitations. Issues such as adverse drug reactions, drug resistance, high development costs, and regulatory complexities continue to pose challenges for pharmaceutical research and development.

In recent years, integrative pharmacological approaches have gained increasing attention as a strategy to overcome limitations associated with single-drug therapies. Combination drug strategies involve the simultaneous or sequential use of multiple therapeutic agents to enhance efficacy, reduce toxicity, and minimize the development of drug resistance. Such approaches are particularly relevant in the management of complex and multifactorial diseases, where targeting a single pathway may not produce optimal therapeutic outcomes. Combination therapy can involve natural compounds with synthetic drugs, multiple synthetic agents, or multi-component herbal formulations.

The integration of natural products with synthetic therapeutics offers promising opportunities for synergistic therapeutic effects. Natural compounds may enhance drug absorption, reduce adverse effects, modulate immune responses, or target complementary biological pathways. These integrative approaches are being explored in areas such as oncology, metabolic disorders, infectious diseases, and neurodegenerative conditions. Moreover, advancements in nanotechnology, drug delivery systems, and pharmacogenomics are facilitating more precise and personalized combination therapies.

Emerging technologies are also transforming pharmacological research. Artificial intelligence, machine learning, bioinformatics, and systems pharmacology enable large-scale data analysis, predictive modeling, and identification of novel therapeutic targets. These tools accelerate drug discovery, optimize clinical trial design, and support personalized medicine initiatives. Precision therapeutics, guided by genetic, environmental, and lifestyle factors, represent a significant advancement toward individualized healthcare.

Furthermore, increasing global health challenges, including chronic diseases, antimicrobial resistance, aging populations, and environmental health concerns, underscore the need for innovative pharmacological solutions. Collaborative efforts among academia, pharmaceutical industries, regulatory agencies, and healthcare providers are essential to translate laboratory findings into safe and effective clinical therapies. Ethical considerations, regulatory frameworks, and sustainability issues must also be addressed to ensure responsible advancement in pharmacological research.

2. Natural Products in Pharmacological Research

Natural products have served as a fundamental source of therapeutic agents throughout the history of medicine and continue to play a crucial role in modern pharmacological research. Derived from plants, microorganisms, marine organisms, and other natural sources, these compounds possess immense structural diversity and biological activity. Many currently used drugs either originate directly from natural sources or are chemically modified derivatives inspired by natural molecules. Their wide-ranging pharmacological properties, including antimicrobial, anticancer, anti-inflammatory, antioxidant, antidiabetic, and neuroprotective activities, highlight their continued relevance in drug discovery and therapeutic development. Advances in analytical technologies, biotechnology, and pharmaceutical formulation have further expanded the scope of natural product research, making it a dynamic and essential area of modern pharmacology.



Figure 1: Natural Product Flow Chart

2.1 Historical Significance and Modern Relevance

Natural products have historically formed the backbone of traditional medicine systems worldwide. Herbal remedies, plant extracts, and natural formulations have been used for centuries to treat diseases and maintain health. Early pharmacological discoveries often relied on empirical observations of medicinal plants and natural substances. Over time, scientific investigation of these traditional remedies led to the identification of numerous bioactive compounds that became the basis for modern pharmaceuticals. For example, several widely used therapeutic agents in oncology, cardiology, infectious diseases, and pain management have natural origins or were developed from natural compound templates.

The continued relevance of natural products in pharmacological research stems from their chemical diversity and biological specificity. Natural compounds often possess complex molecular structures that interact effectively with biological systems, making them valuable leads for drug discovery. Their multitarget activity can be particularly beneficial in managing multifactorial diseases such as cancer, diabetes, inflammatory disorders, and neurodegenerative conditions. Additionally, the growing interest in safer and more sustainable therapeutic options has renewed focus on plant-based and naturally derived medicines.

Microbial metabolites represent another important category of natural products. Many antibiotics, immunosuppressive agents, and anticancer drugs originate from microbial sources, particularly fungi and bacteria. Similarly, marine

organisms such as algae, sponges, and marine microorganisms have emerged as promising sources of novel bioactive compounds due to their unique ecological adaptations and chemical diversity. These marine-derived compounds have shown potential in anticancer, antiviral, anti-inflammatory, and neuroprotective therapies.

In contemporary pharmacological research, natural products are increasingly integrated with advanced scientific techniques. Ethnopharmacological knowledge, combined with modern molecular biology, genomics, metabolomics, and computational modeling, helps identify new drug candidates more efficiently. This integrative approach bridges traditional medicinal knowledge with modern scientific validation, facilitating the development of innovative therapeutics.

2.2 Advances in Extraction and Characterization

Advancements in extraction and analytical technologies have significantly improved the identification, isolation, and characterization of bioactive compounds from natural sources. Traditional extraction methods such as maceration, decoction, and Soxhlet extraction, although widely used, often involve long processing times, high solvent consumption, and potential degradation of sensitive compounds. Modern extraction techniques aim to enhance efficiency, reduce environmental impact, and preserve the biological activity of natural compounds.

Green extraction technologies have gained considerable attention due to their sustainability and efficiency. Supercritical fluid extraction utilizes supercritical carbon dioxide as a solvent, offering advantages such as reduced solvent toxicity, improved selectivity, and minimal environmental impact. Microwave-assisted extraction accelerates extraction processes by enhancing solvent penetration and heat distribution, resulting in improved yield and reduced extraction time. Ultrasound-assisted extraction is another emerging technique that enhances compound release through acoustic cavitation, improving extraction efficiency while preserving compound integrity.

Analytical advancements have also revolutionized natural product research. High-performance liquid chromatography (HPLC) enables precise separation and quantification of complex mixtures of bioactive compounds. Gas chromatography coupled with mass spectrometry (GC–MS) is particularly useful for volatile and semi-volatile compounds, while liquid chromatography–mass spectrometry (LC–MS) provides detailed molecular information for nonvolatile compounds. Nuclear magnetic resonance (NMR) spectroscopy remains a powerful tool for structural elucidation and confirmation of natural products.

In addition to these analytical tools, metabolomics, proteomics, and genomics have contributed significantly to understanding the biological activity and mechanisms of natural compounds. These approaches facilitate the identification of novel therapeutic targets, bioactive molecules, and potential biomarkers, thereby accelerating drug discovery. Integration of computational methods such as molecular docking and in silico screening further enhances the efficiency of natural product-based drug research.

2.3 Challenges in Natural Product Research

Despite their significant therapeutic potential, natural product-based drug discovery faces several challenges that must be addressed to ensure successful translation into clinical applications. One major challenge is variability in phytochemical composition. Environmental factors such as climate, soil conditions, geographic location, harvesting time, and plant

maturity can influence the concentration and composition of bioactive compounds. This variability complicates standardization, quality control, and reproducibility of therapeutic outcomes.

Standardization of natural products remains a critical issue in pharmacological research. Ensuring consistent quality, potency, and safety of herbal preparations requires rigorous quality control measures, including authentication of raw materials, standardized extraction procedures, and validated analytical techniques. Regulatory frameworks for natural products vary across countries, which may hinder global commercialization and clinical acceptance.

Bioavailability is another significant concern. Many natural compounds exhibit poor solubility, limited absorption, rapid metabolism, or instability, which can reduce therapeutic effectiveness. Advances in pharmaceutical formulation, including nanoformulations, liposomal delivery systems, and polymer-based carriers, are being developed to enhance bioavailability, stability, and targeted delivery of natural compounds.

Safety and toxicity evaluation also pose challenges. Although natural products are often perceived as safe, they may produce adverse effects, drug interactions, or toxicity if not properly studied. Comprehensive pharmacological, toxicological, and clinical evaluations are essential to ensure safe therapeutic use.

Furthermore, intellectual property issues, sustainable sourcing, and environmental conservation represent additional concerns. Overharvesting of medicinal plants and marine organisms can threaten biodiversity, highlighting the need for sustainable cultivation and conservation strategies. Biotechnology-based production methods, including plant tissue culture and microbial fermentation, offer potential solutions for sustainable natural product production.

3. Synthetic Therapeutics: Innovations and Developments

Synthetic therapeutics represent a major advancement in modern pharmacological research, offering highly controlled drug design, improved therapeutic specificity, and scalable production processes. Unlike natural products, which are derived from biological sources, synthetic drugs are chemically designed and manufactured using advanced medicinal chemistry, molecular biology, and computational techniques. These therapeutics have transformed the management of various acute and chronic diseases, including cancer, infectious disorders, cardiovascular diseases, metabolic conditions, and neurological disorders. Continuous technological progress has further refined synthetic drug development, enhancing efficacy, safety, and precision in therapeutic interventions.

3.1 Rational Drug Design

One of the most significant developments in synthetic therapeutics is rational drug design, which involves the deliberate design of drug molecules based on knowledge of biological targets and disease mechanisms. Advances in computational modeling, bioinformatics, and structural biology have enabled scientists to design drugs with high specificity toward particular receptors, enzymes, or signaling pathways. Techniques such as molecular docking, quantitative structure–activity relationship studies, and computer-aided drug design facilitate prediction of molecular interactions and optimization of drug candidates before synthesis.

Structure-based drug design relies on detailed knowledge of target protein structures obtained through techniques such as X-ray crystallography and nuclear magnetic resonance spectroscopy. This approach helps identify active binding sites and design molecules that interact efficiently with those sites, improving therapeutic effectiveness while minimizing off-target

effects. Rational drug design has contributed significantly to the development of targeted therapies, particularly in oncology, antiviral treatments, and enzyme inhibition therapies. These innovations have improved drug selectivity, reduced toxicity, and accelerated the drug discovery process.

3.2 Biotechnological Advances

Biotechnology has revolutionized synthetic therapeutics by enabling the development of biologics, recombinant proteins, monoclonal antibodies, vaccines, and gene-based therapies. These biologically derived therapeutics provide highly specific mechanisms of action and are particularly useful in treating complex diseases that are difficult to manage with conventional small-molecule drugs.

Monoclonal antibodies have emerged as a major class of therapeutic agents, especially in cancer treatment, autoimmune disorders, and inflammatory diseases. Recombinant DNA technology allows large-scale production of therapeutic proteins such as insulin, growth factors, and clotting factors with high purity and consistency. Gene therapy, which involves modifying or replacing defective genes, represents a promising frontier in personalized medicine, offering potential cures for genetic disorders and certain chronic diseases.

Advances in biotechnology also include cell-based therapies, immunotherapies, and RNA-based therapeutics. These approaches target disease mechanisms at the molecular and cellular levels, providing more precise and effective treatments. Such innovations are expanding the scope of pharmacological research and paving the way for next-generation therapeutics.

3.3 Advantages and Limitations

Synthetic therapeutics offer several advantages that contribute to their widespread use in modern medicine. They provide consistent chemical composition, controlled purity, and reproducible pharmacokinetic properties. Large-scale manufacturing ensures availability and uniform quality, which is essential for clinical applications. Furthermore, targeted drug design enhances therapeutic efficacy while reducing unintended side effects.

However, synthetic drugs also present certain limitations. Some synthetic compounds may cause adverse effects due to off-target interactions or long-term toxicity. Drug resistance, particularly in antimicrobial and anticancer therapies, remains a significant challenge requiring continuous innovation. Additionally, drug development involves substantial financial investment, lengthy clinical trials, and stringent regulatory requirements, which can delay therapeutic availability.

Ongoing research focuses on overcoming these challenges through improved drug design, advanced delivery systems, pharmacogenomics, and personalized medicine approaches. Integrating synthetic therapeutics with natural product research and combination drug strategies is increasingly recognized as an effective approach to achieving safer, more effective, and sustainable therapeutic outcomes.

4. Combination Drug Strategies in Modern Pharmacology

Section	Aspect	Description
4.1 Rationale for Combination Therapy	Definition	Combination therapy refers to the simultaneous or sequential use of two or more drugs to improve therapeutic outcomes compared with

		single-drug therapy.
	Clinical Application	Widely used in the treatment of infectious diseases, cancer, cardiovascular disorders, metabolic diseases, and chronic inflammatory conditions.
	Purpose	Aims to enhance efficacy, reduce resistance, improve patient compliance, and target multiple disease mechanisms simultaneously.
4.2 Benefits of Combination Therapy	Improved Therapeutic Efficacy	Drugs may act synergistically, producing enhanced therapeutic effects compared with individual drugs.
	Reduction in Drug Resistance	Particularly important in antimicrobial and anticancer therapy, where multiple drugs help prevent resistance development.
	Reduced Toxicity	Lower doses of individual drugs can minimize adverse effects while maintaining efficacy.
	Multi-Target Action	Allows simultaneous targeting of multiple biological pathways or disease mechanisms.
4.3 Natural–Synthetic Drug Combinations	Concept	Integration of natural bioactive compounds with synthetic drugs to enhance therapeutic performance.
	Advantages	Potential for improved efficacy, reduced side effects, better patient tolerance, and complementary mechanisms of action.
	Therapeutic Areas	Commonly explored in oncology, antimicrobial therapy, metabolic disorders, and chronic disease management.
	Research Focus	Emphasis on pharmacokinetic optimization, safety evaluation, and development of novel drug delivery systems.

5. Emerging Technologies Supporting Integrative Pharmacology

Rapid technological advancements are transforming pharmacological research by enabling more precise drug discovery, targeted therapeutic delivery, and personalized treatment strategies. Integrative pharmacology increasingly relies on interdisciplinary innovations such as artificial intelligence, nanotechnology, computational biology, and systems pharmacology to improve therapeutic efficacy and safety. These emerging technologies facilitate a deeper understanding of disease mechanisms, optimize drug design, and enhance clinical outcomes by tailoring treatments to individual patient characteristics. As healthcare challenges become more complex, the adoption of advanced technological approaches has become essential for the development of next-generation pharmacological interventions.

5.1 Artificial Intelligence and Computational Pharmacology

Artificial intelligence (AI) and computational pharmacology have revolutionized modern drug discovery and development processes. AI-driven platforms enable rapid analysis of large biological and chemical datasets, facilitating identification of novel drug targets, prediction of molecular interactions, and optimization of drug candidates. Machine learning algorithms

can analyze genomic, proteomic, and clinical data to identify potential therapeutic compounds with greater efficiency than traditional experimental methods.

Computational pharmacology tools such as molecular modeling, virtual screening, and pharmacokinetic simulations allow researchers to predict drug absorption, distribution, metabolism, excretion, and toxicity profiles before clinical testing. These approaches significantly reduce research costs, shorten development timelines, and improve success rates in drug discovery. Furthermore, AI-based predictive models support personalized medicine by identifying patient-specific treatment responses and minimizing adverse drug reactions. Overall, artificial intelligence is becoming an indispensable component of modern pharmacological research.

5.2 Nanotechnology-Based Drug Delivery

Nanotechnology has emerged as a transformative approach in drug delivery systems, offering enhanced therapeutic precision and improved pharmacological outcomes. Nanocarriers such as liposomes, polymeric nanoparticles, dendrimers, nanoemulsions, and solid lipid nanoparticles provide innovative platforms for delivering drugs with increased stability, solubility, and bioavailability. These delivery systems can protect drugs from degradation, facilitate controlled release, and enable targeted delivery to specific tissues or cells.

Targeted nanocarrier systems are particularly beneficial in treating cancer, neurological disorders, infectious diseases, and chronic inflammatory conditions. By directing drugs specifically to diseased tissues, nanotechnology reduces systemic toxicity and improves therapeutic efficacy. Additionally, nanotechnology supports combination drug delivery, allowing simultaneous administration of multiple therapeutic agents in a single formulation. Continued research in nanomedicine aims to enhance safety, scalability, and regulatory acceptance of these advanced drug delivery technologies.

5.3 Systems Pharmacology and Precision Medicine

Systems pharmacology integrates systems biology, pharmacokinetics, pharmacodynamics, and computational modeling to understand complex interactions within biological systems. This holistic approach considers genetic, environmental, metabolic, and lifestyle factors that influence drug response. By analyzing these interconnected variables, researchers can develop more effective and individualized therapeutic strategies.

Precision medicine, a key outcome of systems pharmacology, focuses on tailoring treatments according to individual patient characteristics, including genetic profiles, disease phenotypes, and environmental influences. This approach enhances therapeutic effectiveness while minimizing adverse effects. Advances in genomics, proteomics, metabolomics, and bioinformatics have facilitated identification of biomarkers that guide personalized treatment decisions.

6. Challenges and Future Perspectives

Despite significant advances in pharmacological research, several challenges continue to influence the successful development and application of integrative therapeutic approaches. One major concern is the **standardization of natural products**, as variability in phytochemical composition due to environmental, geographical, and processing factors can affect therapeutic consistency, safety, and efficacy. Establishing robust quality control measures, validated analytical techniques, and standardized extraction protocols is essential to ensure reproducible pharmacological outcomes.

Another critical challenge involves the **safety and toxicity evaluation of combination therapies**, particularly when natural products are used alongside synthetic drugs. Potential drug–drug interactions, altered pharmacokinetics, and unexpected adverse effects require comprehensive preclinical and clinical investigations. Rigorous toxicological studies and pharmacovigilance are necessary to ensure patient safety and therapeutic reliability.

Regulatory approval complexities also present significant obstacles. Diverse regulatory frameworks across countries, extensive documentation requirements, and long approval timelines can delay the availability of innovative therapies. Harmonization of regulatory guidelines and improved collaboration between researchers, industries, and regulatory authorities may facilitate smoother drug approval processes.

Additionally, achieving cost-effective drug development remains a major priority. Drug discovery and clinical trials involve substantial financial investment, making affordability and accessibility important considerations, especially in developing regions. Adoption of advanced computational tools, artificial intelligence, and streamlined clinical trial designs may help reduce development costs.

References

1. Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., & Supuran, C. T. (2021). Natural products in drug discovery: Advances and opportunities. Nature Reviews Drug Discovery, 20(3), 200–216.
2. Bai, J. P. F., & Abernethy, D. R. (2023). Systems pharmacology and translational science in drug development. Clinical Pharmacology & Therapeutics, 113(1), 17–28.
3. Basile, A., & Rigano, D. (2022). Natural product research in modern drug discovery. Phytochemistry Reviews, 21(2), 481–504.
4. Chan, H. S., Shan, H., Dahoun, T., Vogel, H., & Yuan, S. (2022). Advancing drug discovery via artificial intelligence. Trends in Pharmacological Sciences, 43(9), 681–696.
5. Chen, Y., Liu, X., & Nguyen, K. (2023). Combination therapies in modern pharmacology: Opportunities and safety challenges. Frontiers in Pharmacology, 14, 1187423.
6. Cragg, G. M., & Pezzuto, J. M. (2016). Natural products as a vital source for drug discovery. American Journal of Chinese Medicine, 44(1), 1–20.
7. Ekins, S., Puhl, A. C., Zorn, K. M., Lane, T. R., Russo, D. P., Klein, J. J., & Hickey, A. J. (2019). Exploiting AI for drug discovery. Nature Reviews Drug Discovery, 18(6), 435–454.
8. Ferreira, L. G., Dos Santos, R. N., Oliva, G., & Andricopulo, A. D. (2015). Molecular docking and structure-based drug design strategies. Molecules, 20(7), 13384–13421.
9. Fridman, W. H., Zitvogel, L., Sautès-Fridman, C., & Kroemer, G. (2017). The immune contexture in cancer prognosis and therapy. Nature Reviews Clinical Oncology, 14(12), 717–734.
10. Hughes, J. P., Rees, S., Kalindjian, S. B., & Philpott, K. L. (2011). Principles of early drug discovery. British Journal of Pharmacology, 162(6), 1239–1249.
11. Kola, I., & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery, 3(8), 711–716.

12. Makurvet, F. D. (2021). Biologics vs small molecules in drug development. Journal of Pharmaceutical Sciences, 110(1), 38–46.
13. Moffat, J. G., Rudolph, J., & Bailey, D. (2014). Phenotypic drug discovery. Nature Reviews Drug Discovery, 13(8), 588–602.
14. Mullard, A. (2024). Trends in drug approvals and development pipelines. Nature Reviews Drug Discovery, 23, 87–90.
15. Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010). Improving R&D productivity. Nature Reviews Drug Discovery, 9(3), 203–214.
16. Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., … Pirmohamed, M. (2019). Drug repurposing progress. Nature Reviews Drug Discovery, 18(1), 41–58.
17. Rodrigues, T., Reker, D., Schneider, P., & Schneider, G. (2016). Counting on natural products. Nature Chemistry, 8(6), 531–541.
18. Schork, N. J. (2015). Personalized medicine: Time for one-person trials. Nature, 520(7549), 609–611.
19. Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W. (2014). Computational drug discovery methods. Pharmacological Reviews, 66(1), 334–395.
20. Topol, E. J. (2019). High-performance medicine and AI convergence. Nature Medicine, 25(1), 44–56.
21. Van Norman, G. A. (2016). Drugs, devices, and FDA regulatory pathways. JACC: Basic to Translational Science, 1(6), 399–412.
22. Vasan, N., Baselga, J., & Hyman, D. M. (2019). Precision oncology advances. Nature, 575(7781), 299–309.
23. Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., … Weir, A. (2015). Causes of attrition in drug development. Nature Reviews Drug Discovery, 14(7), 475–486.